Successful treatment of Listeria monocytogenes prosthetic valve endocarditis using rifampicin and benzylpenicillin in combination with valve replacement. (28th February 2017)

• Record Type: Journal Article
• Authors: Hasan, Tasnim; Chik, William; Chen, Sharon; Kok, Jen
• Is Part Of: JMM case reports. Volume 4:Number 2(2017)
• Publication Date: 2017-02-28
• Subjects: Listeria -- endocarditis -- prosthetic valve -- rifampicin; Medical microbiology -- Periodicals; 616.9041
• DOI: 10.1099/jmmcr.0.005085
• Languages: English
• ISSNs: 2053-3721

Abstract

Abstract : Introduction. Listeria monocytogenes is an uncommon cause of prosthetic valve endocarditis (PVE). Recommended antimicrobial therapy typically includes intravenous β-lactams with or without synergistic aminoglycosides. In vitro studies have previously identified antagonism when rifampicin has been used in combination with β-lactams. However, in vivo data of rifampicin use are limited despite its enhanced anti-biofilm activity. Case presentation. A 63-year-old male presented with fever and back pain. L. monocytogenes bacteraemia and bioprosthetic aortic valve endocarditis was confirmed, along with spinal discitis and osteomyelitis. He was successfully treated with benzylpenicillin and rifampicin, in conjunction with valve replacement. Conclusion. Rifampicin remains an alternate agent to use, when there are contraindications to traditional aminoglycoside therapy. Further data on rifampicin use in L. monocytogenes PVE are awaited.